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Abstract 
Background: One schedule for the capsular group B meningococcal vaccine, 
4CMenB, is two doses two months apart for children 12-23 months of age, with a 
booster dose 12-24 months later. This study provides the first data on persistence of 
human serum bactericidal antibody (hSBA) titres up to 4 years of age after initial 
doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age 
compared with vaccine-naïve children. 
Methods: Children previously immunised with two doses of 4CMenB at 12-24 
months of age received a booster at four years of age. Vaccine-naïve age-matched 
toddlers received two doses of 4CMenB. hSBA titres against reference strains 
H44/76, 5/99, NZ98/254 and M10713 were evaluated before and after 4CMenB in 4-
year old children.  
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Results: Of 332 children in the study, 123 had previously received 4CMenB and 209 
were vaccine-naïve controls. Prior to the booster, the proportions of participants 
(comparing previously vaccinated groups with controls) with hSBA titres ≥1:5 were 9-
11% vs 1% (H44/76), 84-100% vs 4% (5/99), 0-18% vs 0% (NZ98/254) and 59-60% 
vs 60% (M10713). After one dose of 4CMenB in previously immunised children the 
proportions achieving hSBA titres ≥1:5 were 100% (H44/76 and 5/99), 70-100% 
(NZ98/254) and 90-100% (M10713).  
Interpretation: Waning of hSBA titres by 4 years of age occurs following two doses 
of 4CMenB administered at 12-24 months, and doses at 12-24 months have a 
priming effect on the immune system. A booster might then be necessary to maintain 
hSBA titres ≥1:5 among those with increased disease risk.  
Trial registration: ClinicalTrials.gov (NCT01717638) 
Funding:  Novartis Vaccines Division 
 
 
Introduction 
Neisseria meningitidis causes meningitis and septicaemia1, with rapid disease onset, 
high case-fatality rate2,3 and increased rates of long-term neurological and non-
neurological sequelae4-11. Over the last 15 years conjugate vaccines have resulted in 
near elimination of endemic disease in countries with high coverage group C vaccine 
programmes12 and marked impact of group A vaccines in Africa13. The majority of 
disease in many countries is now caused by capsular group B N. meningitidis 
(MenB)14. This is the leading cause of meningococcal disease in Canada, with a 
peak incidence of 6.16/100,000/year in children aged <1 year15. A recently licensed 
vaccine (4CMenB) designed primarily to prevent MenB infection was introduced into 
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the routine infant immunisation schedule in the UK in September 201516 and has 
been used in a response to hyperendemic MenB disease in Quebec, Canada17. 
While routine use of the vaccine is intended for infant immunisation, the vaccine may 
be considered in older children for catch-up campaigns or outbreaks. Information on 
duration of protection is therefore needed.   
 
One recommended schedule for 4CMenB is two doses at least two months apart for 
children aged 12-23 months, followed by a booster dose 12-23 months thereafter 
because a single dose does not result in sufficient production and persistence of 
protective antibodies18. Different dosing schedules are used at different ages. Infants 
require additional doses18 and shorter intervals have been used in outbreak 
settings19. At present there are no data on the persistence of bactericidal antibodies 
(on which the correlate of protection is based) through to the pre-school period 
following vaccination of toddlers. 
 
The aims of this follow-on study were to assess: (i) the persistence of human serum 
bactericidal antibody (hSBA) titres at 4 years of age in children previously immunised 
with two doses of 4CMenB in the second year of life, compared with age-matched 
vaccine-naïve children; (ii) the percentage of children with hSBA titres ≥1:5 following 
a booster dose of 4CMenB at 4 years of age; (iii) the proportion of vaccine-naïve 4-
year old children achieving hSBA titres ≥1:5 following two doses of 4CMenB; (iv) 
adverse reactions after 4CMenB in 4-year old children.  
 
Methods 
Locations 
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This study (NCT01717638) was an open label, multi-centre extension to a 
randomised controlled trial conducted at 31 centres in the Czech Republic, Italy, 
Spain and the UK between November 2012 and October 2013 (Supplementary 
Table 1).  
 
Participants 
This study was part of a larger study, of which the primary outcome was persistence 
of hSBA titres in infants given 3 priming doses of 4CMenB as infants and a booster 
dose at 12, 18 or 24 months, reported elsewhere20. 
 
Participants involved in a previous follow-on study were invited to take part in this 
study via an invitation letter. In the previous study three cohorts received two doses 
of 4CMenB at 12 and 14 months (n=239), 18 and 20 months (n=51), or 24 and 26 
months (n=55)21. Of these, 123 were enrolled as the follow-on cohort for this study. A 
further 209 vaccine-naïve participants were recruited as age-matched controls 
(Figure 1). Inclusion criteria: healthy child aged 48-59 months; previous receipt of 
two doses of 4CMenB in the previous study (‘follow-on’ participants) or no doses of 
4CMenB (‘vaccine-naive’ participants). Exclusion criteria: previously ascertained or 
suspected disease caused by N. meningitidis; household contact and/or intimate 
exposure to an individual with laboratory-confirmed N. meningitidis; previous allergic 
reaction to any vaccine component; serious chronic or progressive disease; 
known/suspected immunosuppression; participation in another clinical trial within 90 
days pre-enrolment or during the study; family member of research staff.  
 
Vaccine 
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The investigational vaccine was 4CMenB (Bexsero™, GSK). It contains 50μg each 
of three proteins - Neisseria heparin binding antigen (NHBA), Neisserial adhesin A 
(NadA) and factor H binding protein (fHbp) - and 25μg of outer membrane vesicle 
(OMV) from N. meningitidis strain NZ98/254, plus aluminum hydroxide18. The 
vaccine was administered as 0.5ml intramuscularly.  
 
Procedures 
Follow-on participants received one dose of 4CMenB and had blood samples 
obtained prior to and 30 days post-vaccination. Vaccine-naïve participants received 
two doses of 4CMenB, two months apart, and had blood samples taken before the 
first immunisation and one month after each dose.  
 
For 7 days post-vaccination parents recorded adverse events (AEs) and graded their 
severity. Solicited local AEs were injection site pain/erythema/induration/swelling. 
Solicited systemic AEs were fever (axillary temperature ≥38°C), change in eating 
habit, sleepiness, vomiting, diarrhoea, irritability, arthralgia, headache and rash. AEs 
requiring a physician’s visit and use of antipyretics and/or analgesia were recorded. 
The relationship of AEs to the study vaccine was determined by the study 
investigators, considering temporal relationship and biological plausibility. 
 
Serum bactericidal antibody 
Immunogenicity was assessed by measuring hSBA titres, using human serum as the 
source of exogenous complement22. Assays were performed at Novartis Vaccines 
and Diagnostics (GmbH, Marburg, Germany). The fHbp response was assessed with 
strain H44/76, NadA with strain 5/99, PorA with NZ98/254 and NHBA with M10713. 
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Statistical analysis 
The percentage of children at each blood sampling time point with hSBA titres ≥1:5 
and associated 2-sided 95% exact Clopper-Pearson confidence intervals (CIs) were 
calculated for each indicator strain. An interpolated SBA titre ≥1:5 represented 95% 
confidence that participants achieving this titre had an hSBA titre ≥1:4. A post-
vaccine hSBA titre of ≥1:4 is currently accepted as the presumed protective 
threshold against meningococcal disease23. hSBA geometric mean titres (GMTs) 
were calculated and geometric mean ratios (GMRs) by comparison of post-
immunisation and pre-immunisation values. GMT and GMR with associated 95% CIs 
were computed by taking anti-logs. Sample size for the follow-on participants was 
determined by the number of participants in the previous study whose parents were 
willing to take part. Though the primary aim was descriptive, the secondary aim in 
the vaccine-naïve cohort was to demonstrate a “sufficient” immune response 
following two doses of the vaccine, pre-defined as >70% of participants with hSBA 
≥1:5. Power calculations assumed the actual percentage would be 80%, so 162 
participants were required in the vaccine-naïve cohort for 79% power (5% alpha) to 
demonstrate a sufficient immune response against NZ98/254, providing >99.9% 
power for strains H44/76 and 5/99. Assuming 15% drop-out, enrolment of 190 
participants in the vaccine-naïve control group was required.  
 
Ethics 
Written, informed consent was obtained from parents or legal guardians of 
participants. Ethical approval was obtained from independent review committees at 
all study centres.  
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Results 
Study population 
Of 304 children invited, 123 were recruited into the follow-on cohort; 100 received 
their first dose of 4CMenB at 12 months (group 1), 11 at 18 months (group 2) and 12 
at 24 months (group 3) – 122/123 (99%) completed the study (Figure 1). The 
vaccine-naïve cohort (group 4) included 209 children, of whom 190 (91%) completed 
the study. The demographics of the groups were broadly similar (Table 1).  
 
Immunogenicity  
Persistence of hSBA titre ≥1:5 at 4 years of age in the follow-on cohort (represented 
by the ‘pre-vaccine’ category) was 9-11% against H44/76, 84-100% against 5/99, 0-
18% against NZ98/254 and 59-60% against M10713 (Figure 2). hSBA GMTs were 
<5 in all groups for H44/76 and NZ98/254, but were ≥5 for 5/99 and M10713 (Figure 
3). After the third dose of 4CMenB at 4 years of age, 70-100% of participants had an 
hSBA titre ≥1:5, depending on the target strain (Figure 2). hSBA GMTs post-third 
dose were similar to or higher than the GMTs achieved 1 month after the second 
dose (Figure 3). The GMRs comparing pre- to post-booster vaccine responses were 
highest for strain H44/76 (67-133) and lowest for strain M10713 (5.24-7.35) (Table 
2). 
 
In the vaccine-naïve cohort, 0-5% had hSBA titres ≥1:5 against H44/76, 5/99 and 
NZ98/254 pre-vaccination, and 60% against M10713 (Figure 2). After two doses in 
these previously unvaccinated children 91-100% achieved an hSBA titre ≥1:5, with a 
4-fold rise from baseline in 51-100% of participants, depending on the target strain 
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(Supplementary Figure 1). GMTs after two doses were lower or similar to the post-
booster dose values in the follow-on groups (Figure 3). GMRs were similar or higher 
after two doses compared with post-booster in the follow-on groups, with highest 
GMRs observed with strain 5/99 (GMR=299) and lowest with M10713 (GMR=5.12). 
 
Reactogenicity  
The most commonly reported local AE was injection site pain, occurring in 114/121 
(94%) of the follow-on cohort overall after the booster dose, and in 185/205 (90%) of 
the vaccine-naïve cohort after the first dose and 157/194 (81%) after the second 
dose (Table 3). Sleepiness and irritability were the most common systemic AEs 
overall, occurring after 200/519 (39%) and 188/518 (36%) doses, respectively (Table 
3). Fever ≥38.0°C occurred in 25/121 (21%) of the follow-on cohort after a single 
dose, and in 20/204 (10%) of the vaccine-naïve cohort after the first dose and 16/189 
(8%) after the second dose (Table 3). Fever treatment was given after 73/518 (14%) 
vaccine doses overall, preventive therapy before 49/517 (9%) doses and medical 
attention for fever was sought in 9/517 (2%) cases (Table 3). 
 
There were three reported serious AEs, all resulting in hospitalisation and occurring 
in the vaccine-naïve cohort. None were considered vaccine-related. One child 
developed croup 60 days after the first dose; another child had a head injury with 
concussion, contusion and periorbital haematoma 23 days after the first dose; a third 
child required intravenous fluids for gastroenteritis and dehydration three days after 
the second dose of vaccine. There was one withdrawal (parental decision) due to an 
AE – a child in the vaccine-naïve cohort with moderate injection site pain after the 
first vaccination. 
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Interpretation 
This is the first study to describe waning of bactericidal antibodies in children two 
years or more following immunisation with 4CMenB in the second year of life, 
suggesting additional booster doses may be needed if protection is required beyond 
4 years of age. A single booster dose at 4 years of age was sufficient to boost hSBA 
titres to protective levels in the majority of previously vaccinated children, and two 
doses in vaccine-naïve children provided similar protection, supporting the currently 
licensed schedule in this age group. Although hSBA titre is accepted as the correlate 
of protection against meningococcal disease, and used for vaccine licensure, 
vaccine effectiveness at a population level can only be assessed following vaccine 
use. In the UK, introduction of 4CMenB into the infant schedule resulted in 83% 
effectiveness, with prior in vitro immunogenicity data predicting coverage of 73-
88%24. 
 
One previous study in Europe found variable waning of bactericidal antibodies in the 
first 12 months after two doses of 4CMenB given at 12 and 14 months or 13 and 15 
months25. After 12 months, 56-75% had hSBA titres ≥1:5 against H44/76, 94-97% 
against 5/99 and 6-18% against NZ98/254. With our data this suggests that waning 
of bactericidal antibody against fHbp most commonly occurs >12 months post-
vaccination, whereas waning of anti-PorA antibodies occurs almost entirely within 12 
months in this age group. Little waning of anti-NadA antibodies was seen up to 26 
months post-vaccination. This was unlikely due to ongoing boosting by natural 
exposure, since only 4% of 4 year old vaccine-naive children had hSBA ≥1:5 against 
strain 5/99. Persistence of the vaccine-induced anti-NHBA response was poor as 
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similar proportions of the vaccine-naïve and follow-on cohorts had bactericidal 
antibodies against strain M10713 in this study. The reason for high levels of pre-
existing bactericidal antibodies against M10713 in the vaccine-naïve cohort is 
unknown, but does not appear to significantly impair the vaccine response, with 
similar post-vaccine SBA GMTs compared with NZ98/254. In the only other 
published study of antibody persistence in this age group, hSBA titres ≥1:4 occurred 
in 0-38% (depending on target strain) of three-year old UK children after one dose of 
4CMenB at 12 months of age – confirming the need for two doses in this age 
group26. Similar patterns of antigen-dependent differential waning of bactericidal 
antibodies have been reported after two doses of 4CMenB at 40 months of age27,28. 
Presence of bactericidal antibodies against one of the vaccine antigens may be 
sufficient to ensure protection if the protein is expressed at sufficient levels on the 
bacterial surface. The Meningococcal Antigen Typing System has been designed to 
assess this and aims to predict vaccine coverage based on circulating strains29. 
 
Similar persistence of antibodies at four years of age has been described in children 
after three infant doses and a booster in the second year of life20. This suggests that 
three doses in infants plus a booster is broadly equivalent to two doses in the second 
year of life with respect to antibody persistence to four years. However, this latter 
regime provides no protection to young infants who have the highest incidence of 
disease30. While further doses after four years may be required in individuals at 
elevated risk of disease, incidence rates in immunocompetent children aged ≥5 
years remain very low, until a small increase in adolescence in some populations30.  
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Two doses in 11-17-year-old adolescents resulted in persistence of SBA ≥1:4 in 
≥75% of individuals against all vaccine antigens 18-24 months post-vaccination with 
three doses31. A similar study of a bivalent fHbp MenB vaccine (rLP2086) in 11-18-
year-olds reported hSBA titres ≥1:4 up to 4 years after three doses in >50% of 
participants for three of four target strains32.  
 
Our data suggest that antibody persistence following two doses at 24 months is 
similar to immunisation at 12 or 18 months, although the numbers were small. 
Previous studies have reported significant waning of bactericidal antibodies by 5 
years of age following vaccination at 3 years27,28, suggesting children receiving two 
doses of 4CMenB at 2-3 years of age might require further boosters if ongoing 
protection is required (for example, children with splenic dysfunction or complement 
disorders). Persistence data are needed for 4-10 year-old children in larger studies.   
 
The most common local AE in this study was injection site pain, with rates similar to 
those found in previous studies of 4CMenB in 3-year and 5-year old children26-28. 
The rate of post-immunisation fever was also similar to previous data26.   
The major limitation was the low proportion of participants in the follow-on cohort 
from those who completed the previous study (42% in group 1, 22% in group 2, and 
24% in group 3). There is therefore the potential for selection bias as participants 
who tolerated the previous vaccinations better are more likely to take part. The group 
sizes for those receiving priming doses at 18 and 24 months of age were small, 
making comparisons between the follow-on groups difficult – within this limitation, 
there were no significant differences between the groups. Further studies would be 
required to explore differences between schedules in the second year of life. 
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Two doses of 4CMenB given at 12-24 months prime the immune system against the 
vaccine antigens so that there is a booster effect following a single dose 2 years 
later. The rates at which serum antibody titres to the different vaccine antigens wane 
vary widely, although the implications of this for vaccine effectiveness are yet to be 
established. Children receiving their first doses at 2-3 years of age may require 
further booster doses if ongoing direct protection beyond 4-5 years is required, as 
may be the case for those in high risk groups, although further data in larger cohorts 
are required to confirm this. 
 
Bexsero is a trademark of the GSK group of companies. 
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Figures 
Figure 1. Participant flow diagram 
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The follow-on cohort all received two previous doses of 4CMenB at 12 and 14 months (Group 1), 18 and 20 months (Group 2) or 24 and 26 months (Group 3) in a previous 
study21. The vaccine naïve cohort had not previously received any 4CMenB doses. All children received one dose at 4 years of age, the vaccine naïve cohort were given an 
additional dose two months later. Blood for persistence analysis was taken prior to any doses at four years of age (pre-vaccine timepoint) and for booster analysis 30 days 
after each dose. Safety data were collected after each dose. The flowchart shows the number of participants at each stage of the study. Timepoints where blood was taken for 
measurement of hSBA are shown slightly offset from the pain participant flow because inability to measure SBA did not preclude ongoing involvement of the participant in the 
study (i.e. this did not result in withdrawal or loss to follow-up). n, number of participants; hSBA, human serum bactericidal antibody; 4CMenB, multicomponent meningococcal 
serogroup B vaccine.  
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Figure 2. Proportion of participants with human serum bactericidal antibody (hSBA) titre ≥1:5 at each time point against each strain 
 
Proportion of participants with hSBA titre ≥1:5 at 1 month post-previous dose (Groups 1, 2 and 3 only) based on data from Snape et al.21 Time points from this study include 
pre-vaccine (before first dose, all groups), 1 month post-dose 1 (all groups) and 1 month post-dose 2 (Group 4 only). The pre-vaccine category for Groups 1, 2 and 3 
represents persistence of hSBA following the vaccine doses at 12, 18 or 24 months. Group 1 were not tested for M10713 strains at 1 month following the previous dose in the 
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prior study because the strain was not available. Bars represent overall percentage of participants achieving an hSBA titre ≥1:5, with error bars representing 95% confidence 
intervals.  Data shown separately for the four indicator strains H44/76 (fHbp response), 5/99 (NadA response), NZ98/254 (PorA response) and M10713 (NHBA response). 
hSBA, human serum bactericidal antibody.
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Figure 3. hSBA geometric mean titre (GMT) at each time point against each strain 
 
hSBA GMT at 1 month post-previous dose (Groups 1, 2 and 3 only) based on data from Snape et al.21. Time points from this study include pre-vaccine (before first dose, all 
groups), 1 month post-dose 1 (all groups) and 1 month post-dose 2 (Group 4 only). Group 1 were not tested for M10713 strains at 1 month following the previous dose in the 
prior study because the strain was not available. Points represent overall GMT, with error bars representing 95% confidence intervals.  Data shown separately for the four 
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indicator strains H44/76 (fHbp response), 5/99 (NadA response), NZ98/254 (PorA response) and M10713 (NHBA response). hSBA titre of 1:5 shown as horizontal dashed 
line on each graph to enable comparison as different y-axis scale on each graph. hSBA, human serum bactericidal antibody; GMT, geometric mean titre.  
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Tables  
 
Table 1. Participant demographics 
 Follow-on cohort Vaccine-naïve cohort 
 Group 1 Group 2 Group 3 Group 4 
n 100 11 12 209 
Ages at previous 4CMenB doses (months) 12, 14 18, 20 24, 26 None 
Number of doses in this study 1 1 1 2 (2 months apart) 
Age at first dose in this study (months), mean ± SD 51.7 ± 3.3 53.4 ± 4.3 56.8 ± 1.5 53.7 ± 3.6 
Male sex, n (%) 50 (50) 5 (45) 8 (67) 110 (53) 
Caucasian, n (%) 97 (97) 8 (73) 7 (58) 193 (92) 
Weight (kg), mean ± SD 18.1 ± 2.4a 18.7 ± 2.4b 18.8 ± 1.8c 18.1 ± 2.5d 
Height (cm), mean ± SD 106 ± 4 107 ± 4 108 ± 6 107 ± 5e 
a: n=91; b: n=9; c: n=11; d: n=189; e: n=205 
n, number of participants; hSBA, human serum bactericidal antibody; SD, standard deviation. 
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Table 2. Geometric mean ratios (GMRs) of serum bactericidal antibody titres pre-vaccine compared with post-vaccine 
  
 Follow-on cohort Vaccine-naïve cohort 
Strain Group 1 Group 2 Group 3 Group 4 – Dose 1 Group 4 – Dose 2 
H44/76, GMR (95% CI) 
99 (79, 125) 
n=95 
67 (34, 135) 
n=10 
133 (68, 258) 
n=11 
10 (8.2, 13) 
n=175 
105 (94, 116) 
n=175 
5/99, GMR (95% CI) 
70 (57, 86) 
n=92 
51 (27, 95) 
n=10 
55 (30, 99) 
n=11 
29 (23, 37) 
n=168 
299 (256, 350) 
n=172 
NZ98/254, GMR (95% CI) 
27 (21, 36) 
n=93 
5.96 (2.7, 13) 
n=10 
38 (18, 81) 
n=11 
2.25 (1.84, 2.75) 
n=173 
17 (14, 19) 
n=174 
M10713, GMR (95% CI) 
5.24 (3.91, 7.02) 
n=88 
7.06 (2.92, 17) 
n=9 
7.35 (3.03, 18) 
n=9 
2 (1.62, 2.46) 
n=158 
5.12 (3.95, 6.65) 
n=161 
GMR represents the ratio of geometric mean titre (GMT) post-immunisation to pre-immunisation. Post-immunisation GMT was measured 1 month after each 
dose of vaccine and pre-immunisation GMT prior to any doses given in this study. 95% confidence intervals (CIs) were computed by taking the anti-log of the 
mean and the lower and upper limits of the 95% CI. Data shown separately for the four indicator strains H44/76 (fHbp response), 5/99 (NadA response), 
NZ98/254 (PorA response) and M10713 (NHBA response). GMR, geometric mean ratios; n, participants with available results. 
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Table 3. Number and percentage of participants with solicited local and systemic adverse events up to day 7 post-
vaccination for each dose (day of vaccination = day 1) 
 Follow-on cohort Vaccine-naïve cohort – Group 4 
 Group 1 Group 2 Group 3 Dose 1 Dose 2 
Local symptoms      
Pain – any 
 Severe1 
94/99 (95%) 
19/99 (19%) 
9/10 (90%) 
1/10 (10%) 
11/12 (92%) 
1/12 (8%) 
185/205 (90%) 
27/205 (13%) 
157/194 (81%) 
21/194 (11%) 
Erythema2  
 ≥25mm 
 >50mm 
 >100mm 
 
21/99 (21%) 
9/99 (9%) 
2/99 (2%) 
 
3/10 (30%) 
1/10 (10%) 
0/10 
 
0/12 
0/12 
0/12 
 
43/204 (21%) 
9/204 (4%) 
1/204 (<1%) 
 
34/194 (18%) 
19/194 (10%) 
0/194 
Induration2  
 ≥25mm 
 >50mm 
 >100mm 
9/99 (9%) 
1/99 (1%) 
1/99 (1%) 
1/10 (10%) 
0/10 
0/10 
0/12 
0/12 
0/12 
26/204 (13%) 
3/204 (1%) 
0/204 
 
20/194 (10%) 
4/194 (2%) 
0/194 
Swelling2  
 ≥25mm 
 >50mm 
 >100mm 
20/99 (20%) 
2/99 (2%) 
0/99 
2/10 (20%) 
0/10 
0/10 
4/12 (33%) 
1/12 (8%) 
0/12 
30/204 (15%) 
4/204 (2%) 
1/204 (<1%) 
24/194 (12%) 
4/194 (2%) 
0/194 
Systemic symptoms      
Change in eating habits – any 
  Severe3 
42/99 (42%) 
2/99 (2%) 
0/10 
0/10 
3/12 (25%) 
1/12 (8%) 
49/203 (24%) 
3/203 (1%) 
43/194 (22%) 
2/194 (1%) 
Sleepiness – any 
 Severe1 
52/99 (53%) 
3/99 (3%) 
3/10 (30%) 
0/10 
3/12 (25%) 
0/12 
74/205 (36%)7 
5/205 (2%) 
67/193 (35%) 
2/193 (1%) 
Vomiting – any 
  Severe4 
6/99 (6%) 
0/99 
2/10 (20%) 
0/10 
1/12 (8%) 
0/12 
8/205 (4%) 
0/205 
6/194 (3%) 
0/194 
Diarrhoea – any 
  Severe5 
5/99 (5%) 
0/99 
0/10 
0/10 
2/12 (17%) 
0/12 
11/204 (5%) 
1/204 (<1%) 
8/193 (4%) 
0/193 
Irritability – any 
  Severe1 
53/99 (54%) 
6/99 (6%) 
4/10 (40%) 
0/10 
5/12 (42%) 
0/12 
67/204 (33%) 
8/204 (4%) 
58/193 (30%)7 
5/193 (3%) 
Headache – any 
  Severe1 
20/99 (20%) 
1/99 (1%) 
2/10 (20%) 
0/10 
4/12 (33%) 
0/12 
25/204 (12%) 
1/204 (<1%) 
24/194 (12%) 
1/194 (1%) 
Arthralgia – any 
  Severe1 
28/99 (28%) 
10/99 (10%) 
1/10 (10%) 
0/10 
6/12 (50%) 
1/12 (8%) 
45/203 (22%) 
6/203 (3%) 
40/192 (21%) 
2/192 (1%) 
Rash 13/99 (13%) 0/10 0/12 15/201 (7%) 10/192 (5%) 
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 Follow-on cohort Vaccine-naïve cohort – Group 4 
 Group 1 Group 2 Group 3 Dose 1 Dose 2 
Fever  
≥38.0°C6 
 ≥39.0°C 
 ≥40.0°C 
16/99 (16%) 
0/99 
0/99 
4/10 (40%) 
0/10 
0/10 
5/12 (42%) 
2/12 (17%) 
0/12 
20/204 (10%) 
3/204 (1%) 
2/204 (1%) 
16/189 (8%) 
3/189 (2%) 
0/189 
Fever management 
 Treatment given 
 Preventive therapy given 
 Medical attention sought 
 
18/99 (18%) 
5/99 (5%) 
2/99 (2%) 
 
4/10 (40%) 
2/10 (20%) 
1/10 (10%) 
 
5/12 (42%) 
2/12 (17%) 
0/12 
 
22/204 (11%) 
17/204 (8%) 
2/204 (1%) 
 
24/193 (12%) 
23/192 (12%) 
4/192 (2%) 
1unable to perform daily activity; 2severe erythema, swelling or induration defined as ≥50mm; 3no meals all day; 4requires intravenous hydration; 56 or more 
watery stools per day or requires intravenous hydration; 6axillary temperature; 7Two additional systemic non-severe adverse events occurred within 30 
minutes after vaccination – 1 episode of sleepiness and 1 episode of irritability.   
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Supplementary Information 
Supplementary Results 
Against H44/76, 5/99 and NZ98/254, ≥90% of participants in all follow-on groups 
(with the exception of group 2 [primary doses at 18 and 20 months of age] against 
strain NZ98/254) had ≥4-fold rise in human serum bactericidal antibody (hSBA) titre 
after a single booster dose (Supplementary Figure 1). For strain M10713, 56%-% 
and 67% had a 4-fold rise in hSBA titre after the booster.  
 
After one dose in the vaccine-naïve cohort, 24-90% reached hSBA ≥1:5, depending 
on the target strain (Figure 2), and a 4-fold rise in hSBA titre occurred in 63% against 
H44/76, 86% against 5/99, 17% against NZ98/254 and 21% against M10713. hSBA 
geometric meant titres (GMTs) in the vaccine-naïve cohort before the first dose were 
similar to the follow-on cohorts at the same time point, except strain 5/99 (1.15 vs 
23-69) (Figure 3).   
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Supplementary Table 1. List of study sites 
Country Study Site 
United Kingdom Oxford Vaccine Group, University of Oxford 
Vaccine Institute, St George’s, University of London 
Bristol Children’s Vaccine Centre, University of Bristol 
South West Medicine, Cornwall 
Italy  Fondazione IRCCS Policlinico Mangiagalli e Regina Elena 
Ospedale Maggiore della Carita 
A.O.U. Meyer Dip Scienze per la Salute della Donna e Bambino 
Azienda Osp Padova Dip AIS per la salute Donna e Bambino 
Spain Centro Superior de Investigacion en Salud Publica 
Hospital Universitario Dr Peset de Valencia Servicio de Ped 
Hospital Clinico Universitario de Santiago 
Hospital Xeral Cies 
Czech Republic Ordinace praktickeho lekare - Csukasova 
Ordinace praktickeho lekare – Tyce 
Ordinace praktickeho lekare – Eimerova 
Samostatna ordinace praktickeho lekare - Drazan 
Ordinace praktickeho lekare - Hrunka 
Samostatna ordinace praktickeho lekare - Slavik 
Samostatna ordinace praktickeho lekare - Karlova 
Ordinace praktickeho lekare - Dvorakova 
Ordinace praktickeho lekare - Machytka 
Ordinace praktickeho lekare - Machytkova 
Ordinace praktickeho lekare - Horakova 
Ordinace praktickeho lekare - Brandova 
Ordinace praktickeho lekare - Hanzl 
Ordinace praktickeho lekare - Semerakova 
Ordinace praktickeho lekare - Machackova 
Ordinace praktickeho lekare - Kavalkova 
Ordinace praktickeho lekare - Striteska 
Samostatna ordinace praktickeho lekare - Verdanova 
Samostatna ordinace praktickeho lekare - Zizkova 
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Supplementary Figure 1. Proportion of participants with ≥4-fold rise in hSBA titre from pre-vaccine time-point after one and/or two 
doses of 4CMenB 
 
Proportion of participants with ≥4-fold rise in hSBA titre from pre-vaccine to 1 month post-dose 1 (all groups) and 1 month post-dose 2 (Group 4 only). Bars represent overall 
percentage of participants achieving ≥4-fold rise in hSBA titre, with error bars representing 95% confidence intervals.  Data shown separately for the four indicator strains 
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H44/76 (fHbp response), 5/99 (NadA response), NZ98/254 (PorA response) and M10713 (NHBA response). hSBA, human serum bactericidal antibody; 4CMenB, capsular 
group B meningococcal vaccine. 
